10 research outputs found

    ๊ฐ๋‹ด ์ „์‚ฌ์ฒด ๋ถ„์„์„ ํ†ตํ•œ ๋…ธ์ธ ์ฒœ์‹์˜ ์ƒ๋ฌผํ•™์  ๊ฒฝ๋กœ ๋ถ„์„

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (๋ฐ•์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ์˜๊ณผ๋Œ€ํ•™ ์˜ํ•™๊ณผ, 2019. 2. ์กฐ์ƒํ—Œ.Background: Elderly asthma (EA) shows characteristics different from those of conventional asthma. EA is increasing but its specific pathogenesis remains unclear. Currently, systems biology is widely used in biological research because of the rapid advancement of high-throughput technologies. This study aimed to identify EA-related biological pathways by analyzing genome-wide gene expression profiles in sputum cells using systems biology techniques. Methods: We analyzed gene expression profiles in induced sputum of EA patients and healthy elderly controls. A total of 3,156 gene probes with significantly different expressions between the two groups were identified. We performed hierarchical clustering of genes to classify EA patients. Gene set enrichment analysis (GSEA) and weighted gene co-expression network analysis (WGCNA) were both performed to provide biological information. We also replicated our results using public gene expression data available from Gene Expression Omnibus. Results: Fifty-five EA patients and ten elderly control subjects were enrolled. Two distinct gene clusters were found. Cluster 1 (n=35) showed a lower eosinophil proportion in sputum and less severe airway obstruction compared to cluster 2 (n=20). The replication data set also identified two gene clusters (Cluster 1` and Cluster 2`). We found five gene sets enriched in cluster 1 and three gene sets enriched in cluster 2. Among these, we confirmed that two gene sets were significantly enriched in the replication data set (OXIDATIVE_PHOSPHORYLATION (OXPHOS) gene set in Cluster 1` and EPITHELIAL_MESENCHYMAL_TRANSITION (EMT) gene set in Cluster 2`). These were also enriched in a subgroup analysis that consisted of individuals who had never smoked. We also found four leading edge genes (MRPS11, HSPA9, NUDF4, and ACTA1) in the OXPHOS gene set and two (SNTB1 and FUCA1) in the EMT gene set. WGCNA revealed four modules in cluster 1 and 18 modules in cluster 2. The brown module of cluster 1 and the magenta module of cluster 2were correlated with FEV1/FVC ratio in EA patients. These two modules were also replicated using the replication data set. Conclusion: The findings of two distinct gene clusters in EA and different biological pathways within each gene cluster suggest two different pathogenic mechanisms underlying EA. We postulate that oxidative stress and cellular senescence-associated with aging may be important in the development or progress of EA, and these could be an important development for effectively treating EA.์„œ๋ก : ๋…ธ์ธ ์ฒœ์‹์€ ์ „ํ˜•์ ์ธ ์ฒœ์‹๊ณผ๋Š” ๋‹ค๋ฅธ ํŠน์ง•์„ ๊ฐ€์ง€๊ณ  ์žˆ๋‹ค. ๋…ธ์ธ ์ฒœ์‹์˜ ์œ ๋ณ‘์œจ์€ ์ง€์†์ ์œผ๋กœ ์ฆ๊ฐ€ํ•˜๊ณ  ์žˆ์œผ๋‚˜ ๊ทธ ๋ณ‘๋ฆฌ ๊ธฐ์ „์€ ๋ถˆ๋ถ„๋ช…ํ•˜๋‹ค. ๋ณธ ์—ฐ๊ตฌ๋Š” ๊ฐ๋‹ด์—์„œ ์ถ”์ถœํ•œ ์œ ์ „์ž ๋ฐœํ˜„์„ ์ตœ๊ทผ์˜ ์ƒˆ๋กœ์šด ๋ฐฉ๋ฒ•๋ก ์„ ์ด์šฉํ•˜์—ฌ ๋ถ„์„ํ•˜๊ณ  ์ด๋ฅผ ํ†ตํ•˜์—ฌ ๋…ธ์ธ ์ฒœ์‹๊ณผ ๊ด€๋ จ๋œ ์ƒ๋ฌผํ•™์  ๊ฒฝ๋กœ๋ฅผ ๊ทœ๋ช…ํ•˜๊ณ ์ž ํ•œ๋‹ค. ๋ฐฉ๋ฒ•: ๋…ธ์ธ ์ฒœ์‹ ํ™˜์ž์™€ ์ •์ƒ ๋Œ€์กฐ๊ตฐ์˜ ์œ ๋„ ๊ฐ๋‹ด์—์„œ ์œ ์ „์ž ๋ฐœํ˜„์„ ๋ถ„์„ํ•˜์˜€๋‹ค. ๋‘ ๊ตฐ ๊ฐ„ ์ฐจ๋ณ„ ๋ฐœํ˜„๋˜๋Š” 3156๊ฐœ์˜ ์œ ์ „์ž ํ”„๋กœ๋ธŒ๋ฅผ ํ™•์ธํ•˜๊ณ  ์ด๋ฅผ ์ด์šฉํ•˜์—ฌ ๊ณ„์ธต ํด๋Ÿฌ์Šคํ„ฐ๋ง์„ ์‹œํ–‰ํ•˜์—ฌ ๋…ธ์ธ ์ฒœ์‹ ํ™˜์ž๋ฅผ ๋‘ ํด๋Ÿฌ์Šคํ„ฐ (Cluster) ๋กœ ๊ตฌ๋ถ„ํ•˜์˜€๋‹ค. Gene set enrichment analysis (GSEA)๊ณผ Weighted gene co-expression network analysis (WGCNA)๋ฅผ ํ†ตํ•˜์—ฌ ์œ ์ „์ž ๋ฐœํ˜„์„ ๋ถ„์„ํ•˜์˜€๊ณ  ๋…ธ์ธ ์ฒœ์‹์˜ ์ƒˆ๋กœ์šด ์ƒ๋ฌผํ•™์  ๊ฒฝ๋กœ๋ฅผ ํ™•์ธํ•˜์˜€๋‹ค. ๋˜ํ•œ Gene Expression Omnibus (GEO) ์— ๊ณต๊ฐœ๋œ ์œ ์ „์ž ์ •๋ณด๋ฅผ ์ด์šฉํ•˜์—ฌ ์ด๋Ÿฌํ•œ ๊ฒฐ๊ณผ๋ฅผ ์žฌํ™•์ธํ•˜์˜€๋‹ค. ๊ฒฐ๊ณผ: 55๋ช…์˜ ๋…ธ์ธ ์ฒœ์‹ ํ™˜์ž์™€ 10๋ช…์˜ ์ •์ƒ ๋…ธ์ธ ๋Œ€์กฐ๊ตฐ์ด ์—ฐ๊ตฌ์— ์ฐธ์—ฌํ•˜์˜€๋‹ค. ํด๋Ÿฌ์Šคํ„ฐ ๋ถ„์„์„ ํ†ตํ•˜์—ฌ ๋šœ๋ ทํ•œ ๋‘๊ฐœ์˜ ๊ตฐ์ง‘์ด ํ™•์ธ๋˜์—ˆ๋‹ค. 35๋ช…์˜ ํ™˜์ž๋กœ ๊ตฌ์„ฑ๋œ ์ฒซ๋ฒˆ์งธ ๊ตฐ์ง‘ (Cluster 1)์€ 20๋ช…์˜ ํ™˜์ž๋กœ ๊ตฌ์„ฑ๋œ ๋‘๋ฒˆ์งธ ๊ตฐ์ง‘ (Cluster 2)์— ๋น„ํ•˜์—ฌ ๊ฐ๋‹ด ํ˜ธ์‚ฐ๊ตฌ ๋ถ„์œจ์ด ๋‚ฎ๊ณ  ๊ธฐ๋„ ํ์ƒ‰์ด ๊ฒฝ๋ฏธํ•œ ํŠน์ง•์„ ๋ณด์˜€๋‹ค. GEO์— ๊ณต๊ฐœ๋œ ์œ ์ „์ž ์ •๋ณด๋ฅผ ์ด์šฉํ•˜์—ฌ ํด๋Ÿฌ์Šคํ„ฐ ๋ถ„์„์„ ์‹œํ–‰ํ•˜์˜€์„ ๋•Œ ์—ญ์‹œ ๋‘๊ฐœ์˜ ๊ตฐ์ง‘์ด ํ™•์ธ๋˜์—ˆ๋‹ค (Cluster 1`์™€ Cluster 2`). GSEA ๋ฅผ ์‹œํ–‰ํ•˜์—ฌ Cluster 1์—์„œ 5๊ฐœ์˜ ์œ ์ „์ž ์„ธํŠธ์™€ Cluster 2์—์„œ 3๊ฐœ์˜ ์œ ์ „์ž ์„ธํŠธ์˜ ๋ฐœํ˜„์ด ์ฆ๊ฐ€ํ•˜์—ฌ ์žˆ์Œ์„ ํ™•์ธํ•˜์˜€๋‹ค. GEO์—์„œ ๊ณต๊ฐœ๋œ ์œ ์ „์ž ์ •๋ณด๋ฅผ ์ด์šฉํ•˜์—ฌ ๊ฐ™์€ ๋ฐฉ๋ฒ•์œผ๋กœ ๋ถ„์„ํ•˜์—ฌ ๋ฐœํ˜„์ด ์ฆ๊ฐ€๋˜์–ด ์žˆ๋Š” ์œ ์ „์ž ๊ตฐ์ง‘์„ ํ™•์ธํ•˜์˜€๊ณ  ์ด ์ค‘ 2๊ฐœ์˜ ์œ ์ „์ž ์„ธํŠธ [Cluster 1` ์—์„œ OXIDATIVE_PHOSPHORYLATION (OXPHOS), Cluster 2` ์—์„œ EPITHELIAL_MESENCHYMAL_TRANSITION (EMT))๊ฐ€ ๊ณตํ†ต์ ์œผ๋กœ ๋ฐœํ˜„์ด ์ฆ๊ฐ€๋˜์–ด ์žˆ์Œ์„ ํ™•์ธํ•˜์˜€๋‹ค. ๋˜ํ•œ ์ด ๋‘ ์œ ์ „์ž ์„ธํŠธ๋Š” ๋น„ํก์—ฐ์ž๋“ค๋งŒ์„ ๋Œ€์ƒ์œผ๋กœ ๋ถ„์„ํ•˜์˜€์„ ๋•Œ๋„ ๋ฐœํ˜„์ด ์ฆ๊ฐ€๋˜์–ด ์žˆ์—ˆ๋‹ค. ๋‘๊ฐœ์˜ ์œ ์ „์ž ๊ตฐ์ง‘์„ ์ถ”๊ฐ€๋กœ ๋ถ„์„ํ•˜์˜€์„ ๋•Œ ์ฒซ๋ฒˆ์งธ ๊ตฐ์ง‘์˜ OXPHOS ์œ ์ „์ž ์„ธํŠธ์—์„œ 4๊ฐœ์˜ leading edge ์œ ์ „์ž (MRPS11, HSPA9, NUDF4, ACTA1) ์™€ ๋‘๋ฒˆ์งธ ๊ตฐ์ง‘์˜ EMT ์œ ์ „์ž ์„ธํŠธ์—์„œ 2๊ฐœ์˜ leading edge ์œ ์ „์ž (SNTB1, FUCA1)๋ฅผ ํ™•์ธํ•˜์˜€๋‹ค. WGCNA๋ฅผ ํ†ตํ•œ ๋ถ„์„์—์„œ ์ฒซ๋ฒˆ์งธ ๊ตฐ์ง‘์—์„œ 4๊ฐœ, ๋‘๋ฒˆ์งธ ๊ตฐ์ง‘์—์„œ 18๊ฐœ์˜ ๋ชจ๋“ˆ์„ ํ™•์ธํ•˜์˜€๊ณ , ์ฒซ๋ฒˆ์งธ ๊ตฐ์ง‘์˜ ๊ฐˆ์ƒ‰ ๋ชจ๋“ˆ๊ณผ ๋‘๋ฒˆ์งธ ๊ตฐ์ง‘์˜ ์žํ™์ƒ‰ ๋ชจ๋“ˆ์ด ๋…ธ์ธ ์ฒœ์‹ ํ™˜์ž์˜ FEV1/FVC ๋น„์œจ๊ณผ ์—ฐ๊ด€์ด ์žˆ์Œ์„ ํ™•์ธํ•˜์˜€๋‹ค. ์ด ๋‘ ๋ชจ๋“ˆ์€ GEO ์ž๋ฃŒ๋ฅผ ์ด์šฉํ•œ ๋ถ„์„์—์„œ๋„ ๋ณด์กด๋จ์„ ํ™•์ธํ•˜์˜€๋‹ค. ๊ฒฐ๋ก : ๋…ธ์ธ ์ฒœ์‹ ํ™˜์ž์˜ ๊ฐ๋‹ด์—์„œ ๋‘๊ฐœ์˜ ๋šœ๋ ทํ•œ ์œ ์ „์ž ์„ธํŠธ๊ฐ€ ๊ฐ ๊ตฐ์ง‘์—์„œ ๋ฐœํ˜„์ด ์ฆ๊ฐ€๋˜์–ด ์žˆ์Œ์„ ํ™•์ธํ•˜์˜€๋‹ค. ์ด๋Š” ๋…ธ์ธ ์ฒœ์‹์˜ ๋ณ‘๋ฆฌ ๊ธฐ์ „์—์„œ ๋‘๊ฐœ์˜ ๋‹ค๋ฅธ ์ƒ๋ฌผํ•™์  ๊ฒฝ๋กœ๊ฐ€ ์ž‘์šฉํ•จ์„ ์‹œ์‚ฌํ•˜๋Š” ์†Œ๊ฒฌ์ด๋ผ ํ•  ์ˆ˜ ์žˆ๊ฒ ๋‹ค. ์ด๋Š” ๋…ธ์ธ ์ฒœ์‹์˜ ๋ฐœ์ƒ๊ณผ ์ง„ํ–‰์—์„œ ์ค‘์š”ํ•œ ๊ฒฝ๋กœ๋กœ ๋ณด์ด๋ฉฐ ํ–ฅํ›„ ๋…ธ์ธ ์ฒœ์‹์˜ ์น˜๋ฃŒ์—๋„ ์ค‘์š”ํ•  ์ˆ˜ ์žˆ์„ ๊ฒƒ์œผ๋กœ ๋ณด์ธ๋‹ค.Abstract (English) โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ i Introduction โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 1 Methods โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 6 Results โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 11 Discussion โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 48 References โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 56 Abstract (Korean) โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ iv List of tables Table 1. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 16 Table 2. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 18 Table 3. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 19 Table 4. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 20 Table 5. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 22 Table 6. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 24 Table 7. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 26 List of Figures Figure 1. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 28 Figure 2. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 29 Figure 3. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 30 Figure 4. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 31 Figure 5. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 33 Figure 6. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 34 Figure 7. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 36 Figure 8. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 37 Figure 9. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 38 Figure 10. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 39 Figure 11. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 41 Figure 12. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 42 Figure 13. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 44 Figure 14. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 45 Figure 15. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 46Docto

    ๊ฑด๊ฐ•๋ณดํ—˜ ์‹ฌ์‚ฌํ‰๊ฐ€์› ์ž๋ฃŒ๋ฅผ ํ†ตํ•˜์—ฌ ๋ถ„์„ํ•œ ๋งŒ์„ฑ ์•Œ๋ ˆ๋ฅด๊ธฐ์งˆํ™˜์˜ ์œ ๋ณ‘์œจ ์ถ”์ด

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ์˜ํ•™๊ณผ, 2015. 2. ์กฐ์ƒํ—Œ.Background: Although the prevalence of chronic allergic diseases has increased worldwide for several decades, some developed countries recently have shown a slowdown in the incidence of allergic diseases. The aim of this study was to evaluate the recent trends in the prevalence of asthma and other chronic allergic diseases in Korea. Methods: From a database of approximately 50 million beneficiaries in the Korean National Health Insurance (NHI) and Health Insurance Review and Assessment Service (HIRA), data-sets of patients with diagnoses of atopic dermatitis, allergic rhinitis, and asthma were extracted. We analyzed the annual prevalence of asthma, allergic rhinitis, and atopic dermatitis in Korea from 2009 to 2013. Results: The prevalence per 1,000 people of atopic dermatitis, allergic rhinitis, and asthma in 2013 was 20.3, 127.3, and 39.4, respectively. When divided into 10-year age groups, the prevalence of all three diseases was highest in the age group under 10. The prevalence of atopic dermatitis and allergic rhinitis had a decreasing pattern with older age, but for asthma, it showed an increasing pattern for the age group 30-39 and another peak for the age group 70-79. During the study period from 2009 to 2013, the prevalence of allergic rhinitis steadily increased in all age groups including the fastest growth in the age group under 10 with an annual average growth rate of 3.2%. In contrast, the prevalence of asthma and atopic dermatitis did not increase during the same period and instead showed a decrease in the age group under 10. Conclusion: We analyzed the prevalence of chronic allergic diseases in Korea based on nationwide health insurance data. While the prevalence of allergic rhinitis increased for the past 5 years, the prevalence of asthma and atopic dermatitis did not show an increase. These results suggest that the prevalence of chronic allergic diseases in Korea might have plateaued currently.Abstract (English) โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ i Introduction โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 1 Methods โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 2 Results โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 4 Discussion โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 13 References โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 18 Abstract (Korean) โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ iv List of tables Table 1. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 7 List of Figures Figure 1. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 8 Figure 2. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 9 Figure 3. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 10 Figure 4. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 11 Figure 5. โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™โˆ™ 12Maste

    ๋ถ„์ž ๋™์—ญํ•™ ๋ชจ์‚ฌ๋ฅผ ์ด์šฉํ•œ ๋‚˜๋…ธํฌ๊ธฐ ๊ทน๋ฏธ์„ธ์‚ฌ์˜ ๋ฌผ์„ฑ๊ณผ ์•ˆ์ •์„ฑ ์—ฐ๊ตฌ

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :๊ธฐ๊ณ„ํ•ญ๊ณต๊ณตํ•™๋ถ€,2003.Maste

    3์ถ• ์—ฌ์œ  ์ž์œ ๋„ ์ง์ ‘ ๊ตฌ๋™ ๋ฐฉ์‹ ๋กœ๋ด‡์˜ ๋™์—ญํ•™ ํŒŒ๋ผ๋ฏธํ„ฐ ์ถ”์ •

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์ „๊ธฐ๊ณตํ•™๋ถ€,1999.Maste

    ๋ถ„์ž ๋™์—ญํ•™์„ ์ด์šฉํ•œ ๊ณ ์ฒด ํ‰ํŒ ์œ„์˜ ๋‚˜๋…ธํฌ๊ธฐ ์•ก์  ์ฆ๋ฐœ ํ˜„์ƒ ์—ฐ๊ตฌ

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(๋ฐ•์‚ฌ) --์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :๊ธฐ๊ณ„ํ•ญ๊ณต๊ณตํ•™๋ถ€, 2008.2Docto

    ์ „๊ธฐ๋„๊ธˆ์„ ํ†ตํ•œ ๊ฐ„ํŽธํ•œ ๋‹ˆ์ผˆ-๊ตฌ๋ฆฌ ์ธํ™”์ด‰๋งค์˜ ์ œ์กฐ์™€ ๋ฌผ ์‚ฐํ™”๋ฐ˜์‘์—์˜ ์‘์šฉ

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ํ™”ํ•™์ƒ๋ฌผ๊ณตํ•™๋ถ€, 2017. 2. ๊น€์žฌ์ •.Electrochemical water splitting has attracted great attention since it is the most promising strategy for large-scale hydrogen production. Efficient electrolysis is limited due to sluggish kinetics of oxygen evolution reaction (OER), however, as well as high cost of state-of-art precious metals. Hence, numerous researchers endeavored to develop highly active electrocatalyst with low cost. Indebted to this, this study was focused on synthesis of nickel-copper phosphorous electrocatalyst with high OER activity via facile electrodeposition. Optimization of preparation condition confirmed that nickel-copper phosphorous prepared with electrolyte containing 199:1 of Ni2+/Cu2+ ratio exhibited best performance, which even surpasses the OER activity that of NiP, which is already reported as efficient OER catalyst. Suitable Cu addition resulted in lowered Tafel slope and charge transfer resistance compared to NiP. XPS study revealed that Cu addition enhances the role of Ni-P supporting layer, which lies right underneath the OER active, but thermodynamically unstable Ni hydroxide species. Ni spectra showed higher high-valence-state Ni species when Cu was added in the catalyst. The catalyst was electrodeposited with nano-crystalline phase, explained by XRD patterns. According to SEM image, nickel-copper phosphorous has film-like morphology, with uniform element distribution throughout the surface. The catalyst showed excellent robustness up to 18 hrs of OER operation, as well as high Faradaic efficiency over 99%.Chapter 1. Introduction 1 1.1 Hydrogen as a Promising Renewable Energy Source 1 1.2 Electrochemical Water Splitting 5 1.3 Transition-metal-based Catalysts and their Alloys for Water Oxidation 16 1.4 Electrodeposition for Application in OER Electrocatalyst 19 1.5 Purpose of the Study 22 Chapter 2. Experimental 32 2.1 Preparation of Catalyst 32 2.2 Electrochemical Measurements 35 2.3 Gas Chromatography Measurements 37 2.4 Characterization of Catalyst 41 Chapter 3. Results and Discussion 42 3.1 Optimization of Preparation Condition 42 3.2 Optimization of Catalyst Composition 47 3.3 Characterization of Catalyst 55 3.4 Faradaic Efficiency Calculation 72 Chapter 4. Conclusions 75 Bibliography 77 Abstract 80Maste
    corecore